Safety Analysis of Bevacizumab-Containing Adjuvant Chemotherapy in a Phase II Pilot Trial


Safety Analysis of Bevacizumab-Containing Adjuvant Chemotherapy in a Phase II Pilot Trial
Slides from a presentation at SABCS 2010 and transcribed comments from a recent interview with William J Gradishar, MD (1/4/11)

Crown J et al. Bevacizumab (Bev) in combination with docetaxel (T) and cyclophosphamide (C) as adjuvant treatment (AdjRx) for patients (pts) with early stage (ES) breast cancer (BrCa) and normal HER-2 status. A pilot evaluation. San Antonio Breast Cancer Symposium 2010;Abstract P5-10-17.

Dr Gradishar is Director of Breast Medical Oncology at the Robert H Lurie Comprehensive Cancer Center and Professor of Medicine at the Northwestern University Feinberg School of Medicine in Chicago, Illinois.